Student engagement along the innovation and entrepreneurship process: how Duke student fellows assist OTC in tech assessment, marketing, and investment

Whether it’s evaluating early-stage technologies, helping position start-up projects, or participating in investment decisions, Duke students, trainees, and early-career faculty and staff add depth to OTC’s ability to commercialize Duke innovations. Some technologies have a clear path to commercialization, be it through a previous sponsored research contract or consulting connection between an inventor and industry. […]

Duke Capital Partners joins the Office for Translation & Commercialization

As part of the Board of Trustees’ review of Research, Translation and Commercialization (RTC) at Duke, Duke Capital Partners’ (formerly the Duke Angel Network) move to the Office for Translation & Commercialization optimizes its contributions to Duke’s innovation ecosystem and enhances its members’ meaningful engagement with Duke innovators and entrepreneurs. In FY22, Duke Capital Partners […]

Tune Therapeutics Launches with Pioneering Epigenomic Control Platform to Master Gene Networks, Treat Broad Range of Diseases

Tune Therapeutics, a biotechnology company pioneering the creation of epi-therapeutic medicines, launched today with its powerful and precise genetic tuning platform, TEMPO. This cutting-edge technology dials gene expres-sion up or down to desired levels – with the potential to reverse pathways of cancer, genetic disease, and aging by changing cell fate and function at will.

Venture Day 2022 Highlights Early-stage Life-science Companies in the Triangle

The innovation and entrepreneurial ecosystem across the Research Triangle region is important to our regional economy. Continued growth of the ecosystem relies on collaborations among top research universities often resulting in new business formation, or startups, to help push innovation forward in order to create impact across North Carolina and beyond.

Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) announced that Menarini, with support from Radius, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for elacestrant in patients with ER+/HER2- advanced or metastatic breast cancer.

After Decades of Research, Drug Developed at Duke Receives FDA Approval

The phone rang into the pediatric unit that Louise Markert, M.D., Ph.D., was staffing as a junior faculty member in 1991. Had she not answered, there would have been little hope for the more than one hundred patients who were subsequently treated. The call was from a doctor in Tennessee, seeking insights from Duke’s renowned […]

Bridgestone Invests in Duke Start-up, Tire Technology Company Tyrata

Bridgestone Americas (Bridgestone) today announced a minority investment in tire sensor and data management company Tyrata, Inc. (Tyrata). Using an automated and cost-effective drive-over solution that measures tire tread, Tyrata collects tire wear data and provides actionable, cloud-based analytics. This strategic investment accelerates Bridgestone’s efforts to deploy advanced mobility solutions that improve fleet safety, efficiency […]

Kriya Expands Gene Therapy Pipeline and Establishes its Rare Disease Therapeutic Area Division with the Acquisition of Warden Bio

Kriya Therapeutics, Inc., a fully integrated company pioneering novel technologies and therapeutics in gene therapy, announced today that it has acquired Warden Bio, a company developing novel AAV-mediated gene therapies for glycogen storage disorders (GSDs). Under the agreement, Kriya has obtained exclusive rights to Warden Bio’s five preclinical gene therapy programs. This acquisition serves as […]

Xilis Raises $70 Million Series A Financing to Advance Diagnostic and Drug Discovery and Development Platform Leveraging Proprietary MicroOrganoSphere™ Technology

Xilis, Inc., a pioneering company using its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, today announced the close of a $70 million Series A financing. The round was led by Mubadala Capital, joined by new investors GV (formerly Google Ventures), LSP (one of Europe’s largest healthcare […]